Objective To study the relation between diabetic rat encephalopathy and hippocampal apoptosis, and the therapeutic effect and mechanism of Ginkgo biloba extract. Methods Sixty rats were assigned into control group(NC), diabetic encephalopathy group (DM+B) and EGb-treatment group (EGb) randomly, and every group was further divided into two time points of 1 month (NC_1 ,DM+B_1, EGb_1 ) and 3 month(NC_3 ,DM+B_3, EGb_3 ). The behavioral abnormalities were investigated by water maze test and the apoptosis levels of brain tissue by ELISA. Immunohistochemistry and RT-PCR were performed to determine the protein and mRNA expressions of Bcl-2 and Bax. Results (1) Mild dysfunction of learning and memory was detected in DM+B_1 group, and the dysfunction became worse in DM+B_3 group. The matters were greatly improved in EGb-treatment groups. (2) The expressions of Bcl-2 protein and mRNA were increased in DM+B_1 and DM+B_3 groups, and were stronger in EGb_1 and EGb_3 groups. (3) The expressions of Bax protein and mRNA were obviously increased in DM+B_1 and DM+B_3 groups, and were dramatically reduced in EGb_1 and EGb_3 groups. (4) Compared with control group, the apoptosis level of brain tissue was increased in DM+B_1 group, and obviously greater in DM+B_3 group. In the EGb-treatment groups the levels were dramatically reduced. Conclusions Diabetic encephalopathy may be closely related to hippocampal apoptosis. EGb has an protective effect and the mechanism may be attributed to its effects inhibiting apoptosis.

To compare the degree of glycemic excursions by dynamic glucose monitoring in type 2 diabetes in the elderly when their HbA_1c≤6. 5, The mean blood glucose level and hypoglycemia incidence were observed. The amplitude of glycemic excursions revealed by DGMS was significantly lower in insulin glargine group than in mixed insulin group (P<0.05). The incidence of hypoglycemia were lower in glargine group than in mixed insulin group(P<0.05).

Objective To evaluate apelin level in patients with obesity and different glucose tolerances, investigate relevance of apelin with body mass index(BMI), blood lipid and blood glucose. Methods According to different glucose results of oral glucose tolerance test, 120 subjects were divided into three groups: normal glucose tolerance(NGT),impaired glucose tolerance(IGT) and type 2 diabetes(T2DM). All of the subjects were also divided into obese and non-obese subgroups based on their BMI(≥25kg/m~2 or ＜25kg/m~2 ). Plasma apelin levels were compared among groups of NGT, IGT and T2DM. Fasting plasma glucose(FPG)and 2h postprandial plasma glucose (2hPG) after OGTT, lipid profile and BMI were measured. Results Both fasting and 2h postprandial plasma apelin had significant differences in these groups (P<0.05,or P<0.01). The overweight and obese subgroups in the IGT group and diabetes group had higher apelin levels than their counterpart subgroups in the NGT group. BMI, FPO, systolic blood pressure(SBP) were independent influencing factors for apelin (P<0.05 ,or P<0.01). Conclusions Plasma apelin level is related to obesity and type 2 diabetes.

Objective To assess if the ratio of ApoB/ApoA1 is related to the metabolic syndrome and its components. Methods 709 adults living in Chongqing were enrolled. Weight, height, blood pressure, waist circumferences, fasting plasma glucose(FPG) , fasting serum insulin(FIns) and lipids were measured. ApoB/ApoA1 ratio, BMI and insulin resistance index were calculated. Results ApoB/ ApoA1 ratio was increased in subjects with insulin resistance(IR)and MS. Compared with the low ApoB/ ApoA1 ratio group, the high ApoB/ApoA1 ratio group was more likely to get MS(OR=3.5)and IR(OR =2.3) (P<0.001). Conclusions ApoB/ApoA1 ratio is strongly associated with IR, MS and its components, and a high ApoB/ApoA1 ratio is a valuable marker of MS.

Objective To study the effect of exogenous 3-deoxyglucosone (3-DG) on blood glucose of normal mice. Methods Kunming male mice were divided into two groups: 3-DG (5mg/kg) treatment and control group.At day 1,week 1 and week 2 after treatment, we compared fasting blood glucose,and did the glucose tolerance test in 3-DG group after 2 weeks' 3-DG administration. Results Blood glucose was increased obviously 2h after administration with 3-DG once versus pre-administration and control (7.78±0.694 vs 6.41±0.408,and 6.43±0.43,all higher than control,but no statistical significance (P＞0.05). There were no differences in 6 hour fasting blood glucose after once administration with 3-DG and in 12 hours fasting blood glucose two weeks after administration with 3-DG between 3-DG and Con groups. After 3-DG administration for two weeks,as compared with Con, the 30 minute blood glucose of 3-DG administration mice during OGTT was obviously increased (19.47±1.541 vs 17.22±1.911,P＜0.05), but glucose levels at 60 minute and 120 minute had no changes (P＞0.05). Conclusions Exogenous 3-DG increases the normal mice's blood glucose immediately after once administration with 3-DG and results in up-moving of glucose physiological curve and leads to a light impairment of glucose tolerance when mice were continuously fed with 3-DG for 2 weeks.

Objective To investigate the protective effect of N-acetylcysteine(NAC) on the development of myocardial hypertrophy in diabetic rats induced by streptozotocin. Methods Male SD rats were randomly divided into normal control (NC), control treatment (NCT), diabetic (DM) and diabetes treatment (DMT) groups. NAC was administered at dose of 1.4～1.5g·kg~(-1)·d~(-1) to NCT and DMT groups in the drinking water for 8 weeks. At termination the rats were surgically prepared for hemodynamic measurement, such as systolic blood pressure, heart rate, the rate of left ventricle relaxation (-dp/dt) and the time to maximum relaxation (T). Subsequently, the hearts were removed to assay relative ratio of left ventricle weight versus body weight (LVW/BW) and cardiomyocyte cross sectional areas.Plasma glucose, insulin, 15-F_(2t)-isoprostane(15-F_(2t)-Isop) concentration and superoxide dismutase (SOD) activity were analyzed. Results The LVW/BW ratio and cardiomyocyte areas were significantly attenuated by NAC treatment as compared to DM group (P＜ 0.05). Increases in -dp/dt and SOD activity and the decreases in glucose, 15-F_(2t)-Isop T (P＜ 0.05) were found at the same time. Conclusions NAC can effectively prevent the development of myocardial hypertrophy and improve diastolic function in diabetic rats, which may be related to its antioxidant capacity.

Objective To observe the changes in endothelin(ET), nitric oxide(NO) and C-reactive protein(CRP) before and after the rosiglitazone therapy in patients with impaired glucose tolerance(IGT). Methods 72 IGT patients were divided randomly into 2 groups: rosiglitazone group(n=45) and placebo group(n=27). 15 weeks later, the efficacy of rosiglitazone was compared. Results The levels of ET, CRP were decreased and NO increased significantly in rosiglitazone group compared with those before treatment (ET 54.8±10.0 pg/ml vs 72.8±24.3 pg/ml, P<0.01;CRP 4.58±0.38 mg/L vs 5.99± 0.85mg/L, P<0.01 ; NO 41.0±10.0 μmol/L. vs 31.3±9.0 μmol/L, P<0. 01)). However, the levels of ET,CRP and NO in placebo group did not change singnificantly (P>0. 05). Conclusions Rosiglitazone can singnificantly improve ET, NO, CRP level in IGT patients, which means an additional effect of rosiglitazone on the correlation of inflammation and endothelial disturbance.

Objective To investigate the effects of gabapentin(GBP) on plasma β-endorphin(β-EP) level in the patients with painful diabetic neuropathy(PDN). Methods We detected the plasma β-EP level in 24 PDN patients in the treatment with GBP, 18 PDN patients without GBP treatment, 20 diabetic mellitus patients without PDN and 24 healthy control subjects. Results (1)The level of β-EP in diabetic mellitus patients was lower than in the healthy control(P<0.01). (2)The patients who received GBP had a significant change of β-EP level after treatment(P<0. 01).. Conclusions Gabapentin is effective for the treatment of PDN and its adverse effects are mild. It can lower the plasma β-EP level in the patients with PDN.

Objective To analyzed the use of oral hypoglycemic drugs in our hospital for reference of clinical rational use of this kind of drugs. Methods The sorting methods of defined daily dose (DDDs) and the frequency of oral hypoglycenic drugs were used for analysis. Results The list of leading DDDs was glucosidase inhibitor, which accounted for 31.13 % of the total, followed by biguanides which accounted for 21.49%. Conclusions The glueosidase inhibitor, a new type oral hypoglycemic drugs used for lowering postprandial blood sugar level showed remarkable efficacy and safety, so it is currently the first choice for patients with diabetes.

Objective To investigate the cognitive impairment of middle-aged patients with type 2 diabetes mellitus(T2DM). Methods Wechsler adult intelligence scale-Chinese revised edition (WATS-RC) was used as the tool to examine the cognitive function of middle-aged patients with T2DM and the healthy controls in 51 cases. The t-test was used to compare the differences in score between patients and the control group. The patients were divided into two groups with or without cognitive dysfunction. The logistic regression analysis was made for all the variables to confirm risk factors for the cognitive dysfunction in diabetes. Results The WAITS-RC scores of digit-symbol coding test and block design test were much lower(P<0.05) in diabetes versus control group. The other tests showed no significant difference. The cognitive function was negatively correlated with HbA_1>c and HOMA-IR by logistic regression analysis. Conclusions For middle-aged patients with type 2 diabetes, their cognitive functions such as learning ability, analysis and comprehensive capabilities are impaired. The cognitive function is closely related with HbA_1c and HOMA-IR.